Search

Search Constraints

You searched for: Author/Creator Bakker, Geor

Search Results

1. A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild‐to‐moderate Alzheimer's disease. Issue 1 (23rd February 2022)

2. Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders. Issue 12 (December 2019)

4. Dopamine in high-risk populations: A comparison of subjects with 22q11.2 deletion syndrome and subjects at ultra high-risk for psychosis. (28th February 2018)

5. Effects of copy number variations on brain structure and risk for psychiatric illness: Large‐scale studies from the ENIGMA working groups on CNVs. Issue 1 (21st February 2021)

7. Influence of muscarinic M1 receptor antagonism on brain choline levels and functional connectivity in medication-free subjects with psychosis: A placebo controlled, cross-over study. (30th August 2019)

8. P3‐100: CH 1, 2, AND 3 BASAL FOREBRAIN NUCLEI VOLUMES PREDICT FUNCTIONAL SENSITIVITY TO MUSCARINIC M1 RECEPTOR ANTAGONIST BIPERIDEN ON DELAYED WORD RECALL. (1st July 2019)

9. S172. BRAIN METABOLITES AND THE RELATION WITH COGNITION AND PSYCHOTIC SYMPTOMS IN MEDICATION-FREE PSYCHOSIS AND CONTROLS: A PHARMACOLOGICAL MAGNETIC RESONANCE SPECTROSCOPY STUDY. (1st April 2018)

10. S172. BRAIN METABOLITES AND THE RELATION WITH COGNITION AND PSYCHOTIC SYMPTOMS IN MEDICATION-FREE PSYCHOSIS AND CONTROLS: A PHARMACOLOGICAL MAGNETIC RESONANCE SPECTROSCOPY STUDY. (1st April 2018)